ProSomnus, Inc. Common Stock (NASDAQ:OSA) Q4 2023 Earnings Call Transcript

We recently filed an appeal and were granted a hearing with NASDAQ next month, and we remain optimistic of our potential pathways to regain compliance with minimum listing requirements. Turning now to 2024. We are nearing the completion of the first quarter. We are pleased with the traction of our products so far this year, and as we’ve discussed previously, we usually experience seasonality that results in a 15% to 20% Q4 to Q1 decline in volumes and revenues. But that seasonality impact has been tempered so far in 2024 versus historical trends. We look forward to providing the results for the first quarter of 2024 and guidance for the remainder of 2024 on a future call. Again, thank you for joining us today. I look forward to speaking with you again, and I will now turn the call back to Len for closing remarks.

Len Liptak: Thank you, Brian. Thank you, everyone for joining us today. As Mike mentioned at the beginning of the call, we will not be hosting a Q&A session at the conclusion of today’s call. We remain excited about our prospects to further demonstrate our position as the leading non-CPAP therapy for the 1 billion people worldwide with obstructive sleep apnea. We look forward to providing updates as we progress our business forward, pursue our severe label expansion and take important next steps with our RPMO2 device over the coming quarter. Thank you for your continued support.

End of Q&A: Thank you for your participation in today’s conference. This does conclude the program. You may now disconnect.